Business Context and Reporting Period
Company: Aethlon Medical, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2015
Business Overview: Aethlon Medical develops medical devices to address infectious diseases and cancer, primarily through its lead product, the Aethlon Hemopurifier, which targets circulating viruses and tumor-secreted exosomes. The company also operates a subsidiary, Exosome Sciences, Inc., focused on diagnostic products, and holds Department of Defense (DARPA) contracts for sepsis treatment development.
Key Financial Metrics
| Metric | Fiscal Year 2015 | Fiscal Year 2014 |
|---|---|---|
| Total Revenue | $762,417 | $1,623,769 |
| Operating Loss | $(3,992,853) | $(3,055,928) |
| Net Loss (Attributable to Common Stockholders) | $(6,797,157) | $(13,357,232) |
| Cash and Cash Equivalents (End of Period) | $855,596 | $1,250,279 |
| Working Capital | $630,420 | $(14,169,471) |
| Research & Development Expenses | $1,028,000 | $1,509,000 |
| Convertible Notes Payable (Non-Current) | $155,229 | $776,451 |
Note: The company had no derivative liabilities as of March 31, 2015, compared to $10.7 million in 2014.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 53% ($861,352) primarily due to a reduction in DARPA contract revenue ($630,887 in 2015 vs. $1,466,482 in 2014) following a scope reduction in the contract.
- Net Loss Improvement: Net loss decreased significantly by approximately 49% ($6.6 million) compared to the prior year. This improvement was largely driven by the absence of an $8.5 million loss related to changes in the fair value of derivative liabilities recorded in 2014.
- Debt Restructuring: The company recorded a $2.75 million loss on debt conversions in 2015, compared to $40,256 in 2014, as it converted significant portions of its convertible notes into equity.
- Liquidity Position: Working capital improved from a deficit of $14.2 million in 2014 to a positive $630,420 in 2015, aided by the repayment of related party debts and the conversion of liabilities to equity.
Guidance, Outlook, and Risks
Outlook and Capital Needs: The company expects to continue incurring losses for the foreseeable future. While a June 2015 financing raised approximately $5.6 million in net proceeds (sufficient to fund operations through March 31, 2016), significant additional financing will be required to complete future clinical trials and R&D activities beyond that date.
Clinical Progress:
- Hepatitis C: A U.S. FDA-approved feasibility study is enrolling patients at DaVita MedCenter Dialysis in Houston, Texas.
- Ebola: The FDA approved a supplement to the investigational device exemption to treat up to 20 Ebola-infected persons, though this is not a clinical trial.
- Cancer: An investigator-initiated clinical trial with the University of California, Irvine, was initiated to study plasma exosome concentration in cancer patients.
Material Risks:
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties in cash disbursements and a lack of sufficient accounting personnel.
- Government Contract Dependency: Revenue is almost entirely derived from the DARPA contract. Failure to meet milestones or a decision by DARPA not to exercise the option for the fifth year could substantially reduce revenue.
- Regulatory Approval: The Hemopurifier is a Class III device requiring Premarket Approval (PMA). There is no assurance that clinical trials will demonstrate safety and efficacy or that FDA approval will be obtained.
- Authorized Shares: As of June 2015, substantially all 10 million authorized shares were issued or reserved, limiting the ability to raise capital via equity issuance without increasing the authorized share count.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $5.6 million raised in June 2015 to cover the costs of the ongoing Hepatitis C and Ebola protocols and the new cancer trial.
- DARPA Contract Status: Confirm the likelihood of DARPA exercising the option for the fifth year of the contract and the specific milestones required to secure remaining payments.
- Internal Control Remediation: Review the company's progress in addressing the material weaknesses in internal controls identified in the 10-K.
- Share Authorization: Monitor the company's ability to amend its Articles of Incorporation to increase authorized shares, which is critical for future fundraising.
- Clinical Trial Enrollment: Track the enrollment rates and preliminary safety data from the U.S. Hepatitis C feasibility study and the Ebola treatment protocol.